Sildenafil Tablet, Film Coated
Product Images NDC 33342-536

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 33342-536). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Macleods Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Foil (Foil)

Sildenafil Tablet 20 mg film-coated tablets by Macleods Pharmaceuticals Limited. The label indicates the product name, strength, manufacturer name, country of manufacture (India), and includes a barcode. The layout is repeated multiple times on the image with identical text and barcode.*

FDA Label Image

505 (Sildenafil 20mg 6500s)

Label for Sildenafil Tablets USP 20 mg film-coated tablets in a bulk shipment container. The label indicates a total of 6500 tablets for repackaging only, with storage instructions and manufacturer details for Macleods Pharmaceuticals Limited, located in Baddi, Himachal Pradesh, India. A barcode and NDC 33342-536-58 are visible.*

FDA Label Image

505 (Sildenafil 20mg 90s)

Label for Sildenafil Tablets USP 20 mg film-coated tablets by Macleods Pharmaceuticals Limited. The label includes storage instructions (20° to 25°C with excursions permitted), dispensing advice for pharmacists, and manufacturer information including Macleods Pharma USA, Inc. and Macleods Pharmaceuticals Ltd. The package contains 90 tablets with product NDC 33342-536-10.*

FDA Label Image

505 (Sildenafil Carton Label)

Packaging label for Sildenafil Tablets, USP 20 mg, film-coated oral tablets by Macleods Pharmaceuticals Limited. The label indicates a package of 100 unit-dose tablets (10 x 10). Manufacturer information includes Macleods Pharma USA, Inc., Princeton, NJ, and Macleods Pharmaceuticals Ltd., Baddi, Himachal Pradesh, India. Storage instructions and a barcode are also present.*

FDA Label Image

505 (Sildenafil Figure 1)

A chart illustrating fold change and 90% confidence intervals of area under the curve (AUC) and maximum concentration (Cmax) for various drugs when coadministered with Sildenafil. The vertical line at 1 represents no change relative to Sildenafil alone. Recommendations on dose adjustment and coadministration are provided for each interacting drug listed, including Atorvastatin, Azithromycin, Bosentan, Cimetidine, Erythromycin, Maalox, Oral Contraceptives, Ritonavir, and Saquinavir.*

FDA Label Image

505 (Sildenafil Figure 2)

A horizontal error bar chart illustrating the fold change and 90% confidence intervals for various interacting drugs when combined with sildenafil. The chart compares parameters such as AUC, Cmax, INR, and bleeding time, with recommendations for dose adjustments ranging from "No dose adjustment" to "Coadministration not recommended."*

FDA Label Image

505 (Sildenafil Figure 3)

A line graph showing the change from baseline in 6-minute walk distance (meters) at weeks 4, 8, and 12 in the SUPER-1 study. The graph includes data for Sildenafil 40 mg TID, Sildenafil 80 mg TID, and placebo groups, with mean values and 95% confidence intervals plotted over the weeks of study.*

FDA Label Image

505 (Sildenafil Figure 4)

A horizontal dot plot graph showing placebo-corrected changes in 6-minute walk distance for Sildenafil 20 mg TID compared to placebo. The graph is divided into subgroups by baseline walk distance, etiology, PH criteria, gender, age, mean PAP, and PVR. Each subgroup has data points with confidence intervals for placebo and Sildenafil, illustrating treatment effects across different patient categories.*

FDA Label Image

505 (Sildenafil Figure 5)

A line graph illustrating the percentage of subjects without a clinically worsening event over time, comparing placebo and Sildenafil groups. The x-axis represents days from randomization (0 to 112), and the y-axis shows the percentage without event (0 to 100%). The Sildenafil group maintains a higher percentage without worsening events compared to the placebo group throughout the study period.*

FDA Label Image

Str (Sildenafil Str)

Chemical structure of Sildenafil depicted, showing its molecular arrangement including heterocyclic rings, methyl groups, and carboxyl functional groups consistent with the active ingredient Sildenafil.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.